ANIKAnika Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus
- Revenue
- $113M
- 5.9% YoY
- Operating margin
- -9.8%
- 130% YoY
- EBITDA
- −$6M
- 419% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$30M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear85% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $148M | $114M | $121M | $120M | $113M | 5.9% |
| Operating income | $3M | $4M | $844K | −$5M | −$11M | 117% |
| Net income | $4M | −$15M | −$83M | −$56M | −$11M | 80% |
| Operating cash flow | $8M | $4M | −$2M | $5M | $11M | 107% |
| Capex | $5M | $7M | $5M | $8M | $7M | 12% |
| Stock-based comp | $11M | $14M | $15M | $13M | $10M | 23% |
| Buybacks | $0 | $0 | $5M | $11M | $9M | 13% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $2M | 21 | 120 |
| FY2024 | $5M | $3M | 36 | 91 |
| FY2023 | $4M | $2M | 50 | 92 |
| FY2022 | $6M | $4M | 65 | 89 |
| FY2021 | $4M | $2M | 79 | 99 |